leading biotech company for glp-1 Receptor Agonist Market Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 Top 12 Pharma: Pfizer Tops
Description
GLP-1 receptor agonists work by mimicking the action of endogenous GLP-1, a hormone that stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and promotes satiety through central nervous system pathways
Diabetes Spectr Publ Am Diabetes Assoc
Many commercial plans now cover at least one weight-loss GLP1, but prior authorization is almost always required, and some plans exclude weight-loss medications entirely
Kwon Y, Kim HJ, Lo Menzo E, Park S, Szomstein S, Rosenthal RJ
De Boer SY, Masclee AA, Lam WF, Lamers CB
Absence of evidence is not proof of failure
